In 2018, Kuros Biosciences recorded the first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to fund a phase 2 clinical trial of its spinal fusion product.
Here are three things to know:
1. The company raised gross proceeds of $16.2 million from a capital increase Dec. 13, which it will used to fund the phase 2 clinical study of its proprietary KUR-113 spinal fusion product and advance commercialization of MagnetOs.
2. The phase 2 study of KUR-113 will begin enrolling patients in second quarter 2019, with an anticipated interim readout by the second half of 2020.
3. Michael Grau joined Kuros as CFO and Pascal Longlade, MD, joined as CMO.